Last reviewed 2026-05-23 · How we verify

VLA1553 half dose

Valneva Austria GmbH · Phase 2 active Biologic ✓ Verified May 2026

VLA1553 half dose is a Biologic drug developed by Valneva Austria GmbH. It is currently in Phase 2 development.

VLA1553 is a small molecule vaccine candidate, with a modality similar to cotinine, being studied in a Phase 2 clinical trial for the prevention of Chikungunya Virus Infection in healthy children aged 1 to 11 years. The trial is assessing the safety and immunogenicity of two different dose levels of VLA1553, including a full dose and a half dose, compared to a control group.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	VLA1553 half dose
Sponsor	Valneva Austria GmbH
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VLA1553 half dose CI brief — competitive landscape report
VLA1553 half dose updates RSS · CI watch RSS
Valneva Austria GmbH portfolio CI

Frequently asked questions about VLA1553 half dose

What is VLA1553 half dose?

VLA1553 half dose is a Biologic drug developed by Valneva Austria GmbH.

Who makes VLA1553 half dose?

VLA1553 half dose is developed by Valneva Austria GmbH (see full Valneva Austria GmbH pipeline at /company/valneva-austria-gmbh).

What development phase is VLA1553 half dose in?

VLA1553 half dose is in Phase 2.

Manufacturer: Valneva Austria GmbH — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing